ECSP22074030A - Anticuerpos novedosos - Google Patents

Anticuerpos novedosos

Info

Publication number
ECSP22074030A
ECSP22074030A ECSENADI202274030A ECDI202274030A ECSP22074030A EC SP22074030 A ECSP22074030 A EC SP22074030A EC SENADI202274030 A ECSENADI202274030 A EC SENADI202274030A EC DI202274030 A ECDI202274030 A EC DI202274030A EC SP22074030 A ECSP22074030 A EC SP22074030A
Authority
EC
Ecuador
Prior art keywords
antibodies
novel antibodies
tcr
methods
gamma chain
Prior art date
Application number
ECSENADI202274030A
Other languages
English (en)
Inventor
Pierre Vantourout
Adrian Hayday
Oxana Polyakova
Oliver Nussbaumer
Original Assignee
Gammadelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gammadelta Therapeutics Ltd filed Critical Gammadelta Therapeutics Ltd
Publication of ECSP22074030A publication Critical patent/ECSP22074030A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se proporciona un anticuerpo aislado o un fragmento de este, que se une específicamente a una cadena gamma variable 4 (Vγ4) de un receptor de linfocitos T γδ (TCR) y no a una cadena gamma variable 2 (Vγ2) de un TCR γδ. También se proporcionan métodos de tratamiento y otros usos de dichos anticuerpos junto con métodos para producir dichos anticuerpos.
ECSENADI202274030A 2020-02-24 2022-09-22 Anticuerpos novedosos ECSP22074030A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2002581.3A GB202002581D0 (en) 2020-02-24 2020-02-24 Novel antibodies

Publications (1)

Publication Number Publication Date
ECSP22074030A true ECSP22074030A (es) 2022-10-31

Family

ID=70108379

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202274030A ECSP22074030A (es) 2020-02-24 2022-09-22 Anticuerpos novedosos

Country Status (17)

Country Link
US (2) US20230159638A1 (es)
EP (3) EP4591882A3 (es)
JP (2) JP2023516925A (es)
KR (2) KR20220164473A (es)
CN (2) CN115697401A (es)
AU (2) AU2021225390A1 (es)
BR (2) BR112022016894A2 (es)
CA (2) CA3172340A1 (es)
CL (1) CL2022002296A1 (es)
CO (2) CO2022013542A2 (es)
EC (1) ECSP22074030A (es)
GB (1) GB202002581D0 (es)
IL (2) IL295852A (es)
MX (2) MX2022010239A (es)
PE (1) PE20230438A1 (es)
WO (2) WO2021171002A1 (es)
ZA (1) ZA202209699B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
PE20240591A1 (es) 2021-02-17 2024-03-21 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecificos
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454870A4 (en) * 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
MX2022002075A (es) * 2019-08-16 2022-03-17 Gammadelta Therapeutics Ltd Usos terapeuticos de anticuerpos anti-variable delta 1 de tcr.

Also Published As

Publication number Publication date
IL295852A (en) 2022-10-01
EP4591882A2 (en) 2025-07-30
JP2023514437A (ja) 2023-04-05
US20230159638A1 (en) 2023-05-25
IL295696A (en) 2022-10-01
PE20230438A1 (es) 2023-03-08
GB202002581D0 (en) 2020-04-08
CO2022013542A2 (es) 2022-10-11
AU2021225390A1 (en) 2022-09-22
CA3172340A1 (en) 2021-09-02
CO2022013633A2 (es) 2023-02-16
CN115461369A (zh) 2022-12-09
ZA202209699B (en) 2024-12-18
WO2021171003A1 (en) 2021-09-02
BR112022016671A2 (pt) 2022-11-16
MX2022010239A (es) 2022-11-14
JP2023516925A (ja) 2023-04-21
CN115697401A (zh) 2023-02-03
BR112022016894A2 (pt) 2023-04-04
CL2022002296A1 (es) 2023-03-31
US20230090901A1 (en) 2023-03-23
EP4591882A3 (en) 2025-10-15
CA3168973A1 (en) 2021-09-02
EP4110387B1 (en) 2025-05-21
WO2021171002A1 (en) 2021-09-02
KR20220164473A (ko) 2022-12-13
AU2021228266A1 (en) 2022-10-13
EP4110813A1 (en) 2023-01-04
KR20220145894A (ko) 2022-10-31
EP4110387A1 (en) 2023-01-04
MX2022010383A (es) 2022-09-05

Similar Documents

Publication Publication Date Title
ECSP22074030A (es) Anticuerpos novedosos
CY1124091T1 (el) Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
AU2019218516A1 (en) Antibodies to T cell immunoreceptor with ig and itim domains (TIGIT) and uses thereof
MX2021003608A (es) Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente.
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
CL2020001726A1 (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
PE20071312A1 (es) Anticuerpos contra il-22 humana
BR112018075688A2 (pt) anticorpos anti-c5 e métodos de uso
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
BR112023003366A2 (pt) Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
MX2023000547A (es) Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
CL2023001509A1 (es) Anticuerpos multiespecíficos y combinaciones de anticuerpos
MX2021015698A (es) Integración dirigida de configuraciones aleatorias de ácidos nucleicos.
BR112022021077A2 (pt) Anticorpos humanizados antifator bb de complemento e uso dos mesmos
CO2026000998A2 (es) Anticuerpos anti-proteína a-beta, métodos y usos de estos
MX2022002324A (es) Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos.
JOP20250161A1 (ar) الأجسام المضادة لـ unc5c
CO2025005325A2 (es) Anticuerpos anti-cd28
CO2024009846A2 (es) Anticuerpos de afinidad alta de dominio único y métodos de uso de estos
WO2020166810A3 (ko) 항체의 불변부위로만 구성된 항체 단편 및 이의 용도
AR132064A1 (es) Anticuerpos anti-cldn6 y métodos de uso